Full Business Value: Supernus Pharmaceuticals (SUPN)

Brandmark of supernus.com (SUPN)

Supernus Pharmaceuticals (SUPN) ensures stable supplies of therapies for nervous system disorders, mitigating risks by diversifying its raw material suppliers. The price indicator on the chart confirms a business valuation of 2104.20. Supernus Pharmaceuticals (SUPN) aims for dominance in the treatment of epilepsy and ADHD through active R&D and the acquisition of biotech startups. The firm's environmental profile is limited to basic waste control and office energy efficiency.

Supernus Corp (SUPN) - Total Company Value from 11/23/2025 to 10/30/2026

Supernus Pharmaceuticals - analytical breakdowns and key metrics (SUPN)

- market price and analyst price targets:
Stock Price Supernus Pharmaceuticals, Inc.|SUPN - Price Target Chart
- company stock exchange capitalization indicators:
Market Valuation Supernus|SUPN - Total Company Value
- book capitalization indicators:
Equity per Share Supernus|SUPN - Company Book Value|Capitalization to Book Value Ratio supernus.com|SUPN - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Supernus Pharmaceuticals|SUPN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital supernus.com|SUPN - Company Debts|Debt to Net Assets Ratio Supernus|SUPN - Company Long-Term Debt|Short-Term Debt Supernus|Interim Coverage Ratio supernus.com
- earnings and valuation multiples indicators:
SUPN - Net Income
Analysis of all company metrics:Supernus Pharmaceuticals, Inc.
Manufactured product of Supernus Pharmaceuticals

The enterprise value dynamics reflect the market valuation of Supernus Pharmaceuticals (SUPN), whose capitalization is based on the sale of patented CNS therapy drugs. This metric aggregates the market value of equity and debt obligations minus cash and cash equivalents, determining the actual acquisition threshold of the business. Understanding this metric allows an investor to assess the premium paid for the company and avoid capital stagnation when buying at the peak.

Competitors of Supernus Pharmaceuticals (SUPN)

Enterprise Value Biogen Inc BIIB|NBIX - Total Company Value|Full Business Value RGC|Axsome Therapeutics (AXSM) - Total Company Value|Business Value ACAD|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value CPRX|DNLI - Total Enterprise Value|Harmony Biosciences - Real Price to Acquire Entire Company|Enterprise Value biohavenpharma.com BHVN|AMLX - Total Company Value|Value Adjusted for Debt and Cash TRVI (Trevi Therapeutics Inc)|Praxis Medicines (PRAX) - Total Company Value|Total Enterprise Value Anavex Life Sciences Corp (AVXL)|Total Company Value CeriBell, Inc.|Prothena Corp (PRTA) - Company Buyout Price|Real Price to Acquire Entire Company ALEC (Alector, Inc.)|Enterprise Value Annexon Biosciences (ANNX)|Total Company Value Omeros OMER|NGNE (Neurogene Therapeutics) - Full Business Value|AC Immune - Enterprise Value|Total Enterprise Value voyagertherapeutics.com|Neumora Therapeutics, Inc. (NMRA) - Total Company Value|Scilex Holding - Value Adjusted for Debt and Cash|Total Company Value Tevogen Bio Holdings, Inc.|Business Value ACOG (Alpha Cognition Corp)|Real Price to Acquire Entire Company CGTX (Cognition Therapeutics, Inc.)|Enterprise Value inhibikase.com (IKT)|Total Company Value Cassava Sciences SAVA|Company Buyout Price Assertio Holdings (ASRT)|COYA: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash VTGN (Vistagen Therapeutics)|ovidrx.com (OVID) - Total Company Value|Full Business Value ABOS (acumenpharm.com)|CRVO (CervoMed) - Enterprise Value|ATHE: Value Adjusted for Debt and Cash|Enterprise Value CLNN|Enterprise Value pepgen.com (PEPG)|Total Company Value Jupiter Neurosciences JUNS|Value Adjusted for Debt and Cash RLMD|ANVS - Total Company Value|Grace Therapeutics, Inc. (GRCE) - Real Price to Acquire Entire Company|AIFF: Enterprise Value|Klotho Neurosciences (KLTO) - Enterprise Value|NRSN (NeuroSense Therapeutics Ltd) - Enterprise Value|Real Price to Acquire Entire Company revivapharma.com (RVPH)|Enterprise Value MTVA|NRXS - Total Enterprise Value|Helius Medical Technologies - Real Price to Acquire Entire Company|Enterprise Value Passage Bio Inc. PASG|NEUP: Real Price to Acquire Entire Company|minervaneurosciences.com - Aggregate Business Value|ATHA: Enterprise Value|ADXN - Company Buyout Price|ALZN (Alzamend Neuro Inc.) - Enterprise Value|Real Price to Acquire Entire Company Cyclerion (CYCN)|Enterprise Value PTIX|Enterprise Value pasitheaclinics.com (KTTA)|Total Company Value Cortigent CRGT|Avenue Therapeutics Inc. - Total Company Value|BCLI - Total Company Value|Company Buyout Price Cara Therapeutics Inc CARA|Chromocell Therapeutics (CHRO) - Total Company Value|ELYM - Company Buyout Price|Real Price to Acquire Entire Company ITCI|Enterprise Value Longboard Pharmaceuticals Inc|Total Company Value Marinus (MRNS)|NKGN: Full Business Value|Total Company Value NeuroBo Pharmaceuticals NRBO|SAGE: Business Value|SNPX - Total Company Value|TRVN (Trevena Inc.) - Business Value|VIGL: Enterprise Value|Total Enterprise Value anewmeds.com (WENA)|Real Price to Acquire Entire Company CERE